Principia Biopharma was founded on the principle of developing drugs with higher benefit and lower risk to improve patient outcomes and experience. We have a revolutionary way to design drugs that are more selective in order to achieve high efficacy while lowering the risk of side effects.
We are currently enrolling patients in the following clinical trials:
Phase 2 clinical trial with PRN1008 for pemphigus vulgaris, an autoimmune blistering skin disorder that has limited options for treatment. Clinical trial information can be found here (https://www.clinicaltrials.gov/ct2/show/NCT02704429) and information related to the disease can be found here (http://www.pemphigus.org/).
Phase 1 dosing and safety study with PRN1371, a selective, oral, FGFR 1-4 inhibitor in patients with solid tumors. Clinical trial information can be found here (https://www.clinicaltrials.gov/ct2/show/NCT02608125).
Immune Thrombocytopenic Purpura
Phase 1/2 clinical trial with oral PRN1008 for Immune Thrombocytopenic Purpura (ITP), an autoimmune disease causing low platelet levels in the blood. Clinical trial information can be found here (https://clinicaltrials.gov/ct2/show/NCT03395210?term=PRN1008&rank=1).
Please check back again for updates on future clinical trials.